| Name | Title | Contact Details |
|---|
Medical Supply Corporation is a Ferndale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biorez is dedicated to helping patients return to full activity sooner and safer following debilitating ligament and tendon injuries. We have developed the BioBrace™ scaffold, a new implant technology to reinforce tendon and ligament repairs and to facilitate tissue regeneration. Through our proprietary open porous architecture, and use of biomaterials, the BioBrace™ has been engineered to provide a high degree of bio-inductivity to promote rapid tissue regeneration, a biomechanical profile to reinforce repairs throughout the full healing profile, and full absorption overtime to fully restore the anatomy to its normal state. Early pre-clinical work suggests the BioBrace will deliver on the promise of a superior tissue scaffold to accelerate rehabilitation, regenerate functional tissue, and improve overall outcomes. Biorez is a VC-backed startup located in New Haven, CT.
Mississippit Valley Regional Blood Center is a Davenport, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inergetics is a leading developer of advanced proprietary nutritional products that improve overall health, physical recovery, athletic performance and quality of life for patients and consumers. Whether it`s maintaining a healthy diet, gaining strength, increasing energy, or helping to maintain your activity level at an advanced age, Inergetics offers a line of nutritional supplement that fits your lifestyle, and which you can consistently rely on.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.